---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003087"
form_type: "8-K"
ticker: "BYSI"
cik: "0001677940"
company_name: "BeyondSpring Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:50:03.589066+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BeyondSpring Q1 net loss from continuing ops $2.6M; Plinabulin data show promise in PD-1 resistant cancers

## Summary
- Net loss from continuing ops $2.6M, up 24% YoY; R&D expense $0.9M, G&A $1.7M.
- Plinabulin combinations showed durable responses in metastatic NSCLC and Hodgkin lymphoma failing PD-1/L1 inhibitors.
- SEED's RBM39 degrader achieved complete tumor regression in Ewing sarcoma models; IND filing on track for mid-2025.
- SEED reported as discontinued ops after Jan 2025 sale of Series A-1 shares; BeyondSpring retains ~40% stake.
- Phase 1 trial of Plinabulin + PD-1 inhibitor + radiation at MD Anderson showed >19-month duration in heavily pretreated Hodgkin lymphoma.

## SEC filing metadata
- accession: 0001171843-25-003087
- form_type: 8-K
- ticker: BYSI
- cik: 0001677940
- company_name: BeyondSpring Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677940/000117184325003087/0001171843-25-003087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677940/000117184325003087/f8k_051225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003087
- JSON: https://secwatch.observer/filing/0001171843-25-003087.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.